glp-1 psoriatic arthritis The list of conditions for which drugs provides benefit independent of weight loss keeps growing. Add | Eric Topol, MD GLP-1 Agonists and Psoriasis: A

Regulatory activities, including Food and Drug Administration and European Medicines Agency actions Regulatory actions have evolved in response to emerging safety concerns

Ive opened boxes where medication packaging looked like an afterthought

Most patients complete follow-up labs every 36 months to track kidney function, blood sugar, and overall progress

[DOI] [PMC free article] [PubMed] [Google Scholar] 5.Kalra S, Bhattacharya S, Kapoor N

In summary, GLP-2 has a significant inhibitory effect on bone resorption with minimal impact on bone formation, resulting in increased BMD

Consequently, governments, payers, and employers are beginning to adopt these agents as core components of preventive and chronic disease management strategies, driving exponential market demand